JP4970851B2 - 金コロイドの製造方法及び金コロイド - Google Patents
金コロイドの製造方法及び金コロイド Download PDFInfo
- Publication number
- JP4970851B2 JP4970851B2 JP2006156041A JP2006156041A JP4970851B2 JP 4970851 B2 JP4970851 B2 JP 4970851B2 JP 2006156041 A JP2006156041 A JP 2006156041A JP 2006156041 A JP2006156041 A JP 2006156041A JP 4970851 B2 JP4970851 B2 JP 4970851B2
- Authority
- JP
- Japan
- Prior art keywords
- gold
- colloid
- particle size
- ascorbate
- colloidal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims description 115
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 239000002245 particle Substances 0.000 claims description 107
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 76
- 239000000084 colloidal system Substances 0.000 claims description 43
- 239000002253 acid Substances 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 37
- 239000003638 chemical reducing agent Substances 0.000 claims description 35
- 235000010323 ascorbic acid Nutrition 0.000 claims description 27
- 239000011668 ascorbic acid Substances 0.000 claims description 27
- 229940072107 ascorbate Drugs 0.000 claims description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 15
- 230000006911 nucleation Effects 0.000 claims description 15
- 238000010899 nucleation Methods 0.000 claims description 15
- 229910052737 gold Inorganic materials 0.000 claims description 9
- 239000010931 gold Substances 0.000 claims description 9
- 239000012266 salt solution Substances 0.000 claims description 8
- JAJIPIAHCFBEPI-UHFFFAOYSA-N 9,10-dioxoanthracene-1-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)O JAJIPIAHCFBEPI-UHFFFAOYSA-N 0.000 claims 6
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 40
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 23
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 16
- 239000011755 sodium-L-ascorbate Substances 0.000 description 15
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- 229960005070 ascorbic acid Drugs 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 150000004685 tetrahydrates Chemical class 0.000 description 11
- 239000002211 L-ascorbic acid Substances 0.000 description 10
- 235000000069 L-ascorbic acid Nutrition 0.000 description 10
- 239000000032 diagnostic agent Substances 0.000 description 9
- 229940039227 diagnostic agent Drugs 0.000 description 9
- 229910021642 ultra pure water Inorganic materials 0.000 description 8
- 239000012498 ultrapure water Substances 0.000 description 8
- 229960004106 citric acid Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- -1 diallyl citrate Chemical compound 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- ZVUZTTDXWACDHD-UHFFFAOYSA-N gold(3+);trinitrate Chemical compound [Au+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O ZVUZTTDXWACDHD-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MBXRXCODWDRGEU-JLAZNSOCSA-N (2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-4-iodo-2H-furan-5-one Chemical compound OC[C@H](O)[C@H]1OC(=O)C(I)=C1O MBXRXCODWDRGEU-JLAZNSOCSA-N 0.000 description 1
- LGBPWIAXPVUTMY-JLAZNSOCSA-N (2r)-3,4-dihydroxy-2-[(1s)-1-hydroxyethyl]-2h-furan-5-one Chemical compound C[C@H](O)[C@H]1OC(=O)C(O)=C1O LGBPWIAXPVUTMY-JLAZNSOCSA-N 0.000 description 1
- RTPBEMVDAXPYRC-JLAZNSOCSA-N (2r)-4-amino-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-2h-furan-5-one Chemical compound NC1=C(O)[C@@H]([C@@H](O)CO)OC1=O RTPBEMVDAXPYRC-JLAZNSOCSA-N 0.000 description 1
- JAQCMKHAAXSKJO-JLAZNSOCSA-N (2r)-4-bromo-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-2h-furan-5-one Chemical compound OC[C@H](O)[C@H]1OC(=O)C(Br)=C1O JAQCMKHAAXSKJO-JLAZNSOCSA-N 0.000 description 1
- BVEGHOBWEPNMCC-JLAZNSOCSA-N (2r)-4-chloro-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-2h-furan-5-one Chemical compound OC[C@H](O)[C@H]1OC(=O)C(Cl)=C1O BVEGHOBWEPNMCC-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-DUZGATOHSA-N (5r)-5-[(1r)-1,2-dihydroxyethyl]oxolane-2,3,4-trione Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-DUZGATOHSA-N 0.000 description 1
- COBKSGNGDLRBNE-CLTAVNFZSA-N (5r)-5-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-5-methylfuran-2-one Chemical compound OC[C@H](O)[C@@]1(C)OC(=O)C(O)=C1O COBKSGNGDLRBNE-CLTAVNFZSA-N 0.000 description 1
- YZQGFCOUFDWVGL-RNHFCUEFSA-N (5r)-5-[(1s)-1,2-dihydroxyethyl]-5-ethyl-3,4-dihydroxyfuran-2-one Chemical compound OC[C@H](O)[C@@]1(CC)OC(=O)C(O)=C1O YZQGFCOUFDWVGL-RNHFCUEFSA-N 0.000 description 1
- TWUZWTIVCCRAAD-UHFFFAOYSA-N 2-(2-butoxy-2-oxoethyl)-2-hydroxybutanedioic acid Chemical compound CCCCOC(=O)CC(O)(C(O)=O)CC(O)=O TWUZWTIVCCRAAD-UHFFFAOYSA-N 0.000 description 1
- FKBLOGDSDFJGKB-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;rubidium(1+) Chemical compound [Rb+].[Rb+].[Rb+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FKBLOGDSDFJGKB-UHFFFAOYSA-K 0.000 description 1
- YNOXCRMFGMSKIJ-UHFFFAOYSA-N 2-methylcitric acid Chemical compound OC(=O)C(C)C(O)(C(O)=O)CC(O)=O YNOXCRMFGMSKIJ-UHFFFAOYSA-N 0.000 description 1
- KGYXYKHTHJPEBX-UHFFFAOYSA-N 5-ethoxy-3-ethoxycarbonyl-3-hydroxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC(O)(CC(O)=O)C(=O)OCC KGYXYKHTHJPEBX-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NWLGMMPWCMWIQS-SSDLBLMSSA-N C(CC)[C@]1(C(=C(C(=O)O1)O)O)[C@@H](O)CO Chemical compound C(CC)[C@]1(C(=C(C(=O)O1)O)O)[C@@H](O)CO NWLGMMPWCMWIQS-SSDLBLMSSA-N 0.000 description 1
- OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 229910003767 Gold(III) bromide Inorganic materials 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- HWMVXEKEEAIYGB-UHFFFAOYSA-K Isocitric acid, DL- Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C(O)C(C([O-])=O)CC([O-])=O HWMVXEKEEAIYGB-UHFFFAOYSA-K 0.000 description 1
- WOFVPNPAVMKHCX-UHFFFAOYSA-N N#C[Au](C#N)C#N Chemical compound N#C[Au](C#N)C#N WOFVPNPAVMKHCX-UHFFFAOYSA-N 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 1
- ZHCMFLNQEZSPKB-UHFFFAOYSA-N azanium;2-hydroxypropane-1,2,3-tricarboxylic acid;acetate Chemical compound [NH4+].CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O ZHCMFLNQEZSPKB-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 229940057975 ethyl citrate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- OVWPJGBVJCTEBJ-UHFFFAOYSA-K gold tribromide Chemical compound Br[Au](Br)Br OVWPJGBVJCTEBJ-UHFFFAOYSA-K 0.000 description 1
- 229940014053 gold tribromide Drugs 0.000 description 1
- NIXONLGLPJQPCW-UHFFFAOYSA-K gold trifluoride Chemical compound F[Au](F)F NIXONLGLPJQPCW-UHFFFAOYSA-K 0.000 description 1
- PMCMJPXEJUKOAO-UHFFFAOYSA-M gold(1+);bromide Chemical compound [Au]Br PMCMJPXEJUKOAO-UHFFFAOYSA-M 0.000 description 1
- IZLAVFWQHMDDGK-UHFFFAOYSA-N gold(1+);cyanide Chemical compound [Au+].N#[C-] IZLAVFWQHMDDGK-UHFFFAOYSA-N 0.000 description 1
- SDQPNEPNURFLTA-UHFFFAOYSA-M gold(i) fluoride Chemical compound [Au]F SDQPNEPNURFLTA-UHFFFAOYSA-M 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- ZXPXXYCBWQCVNK-UHFFFAOYSA-M hydroxy(oxo)gold Chemical compound O[Au]=O ZXPXXYCBWQCVNK-UHFFFAOYSA-M 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- IHAQDFLGBNNAEH-RXSVEWSESA-M lithium (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-olate Chemical compound O=C1C(O)=C([O-])[C@H](O1)[C@@H](O)CO.[Li+] IHAQDFLGBNNAEH-RXSVEWSESA-M 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 229940074358 magnesium ascorbate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- YWORCEHQVMOKDM-UHFFFAOYSA-H tricalcium;1-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)C(O)C(C([O-])=O)CC([O-])=O.[O-]C(=O)C(O)C(C([O-])=O)CC([O-])=O YWORCEHQVMOKDM-UHFFFAOYSA-H 0.000 description 1
- CXRJQXLAHFIBCX-UHFFFAOYSA-K tricesium 1-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Cs+].[Cs+].[Cs+].OC(C(CC([O-])=O)C([O-])=O)C([O-])=O CXRJQXLAHFIBCX-UHFFFAOYSA-K 0.000 description 1
- WDNRWJRRUZRRNB-UHFFFAOYSA-K tricesium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Cs+].[Cs+].[Cs+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WDNRWJRRUZRRNB-UHFFFAOYSA-K 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- GCZKMPJFYKFENV-UHFFFAOYSA-K triiodogold Chemical compound I[Au](I)I GCZKMPJFYKFENV-UHFFFAOYSA-K 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- BORGOURGDKLMHZ-UHFFFAOYSA-K tripotassium;1-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[O-]C(=O)C(O)C(C([O-])=O)CC([O-])=O BORGOURGDKLMHZ-UHFFFAOYSA-K 0.000 description 1
- PLCFYBDYBCOLSP-UHFFFAOYSA-N tris(prop-2-enyl) 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound C=CCOC(=O)CC(O)(CC(=O)OCC=C)C(=O)OCC=C PLCFYBDYBCOLSP-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- POZPMIFKBAEGSS-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O POZPMIFKBAEGSS-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/0004—Preparation of sols
- B01J13/0043—Preparation of sols containing elemental metal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
- B22F1/0545—Dispersions or suspensions of nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
- Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Composite Materials (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
- Colloid Chemistry (AREA)
Description
塩化金酸四水和物0.17g(4.1×10−4mol)と、クエン酸三ナトリウム二水和物0.49g(1.6×10−3mol)とを、それぞれ超純水25mlと100mlに溶解させて、塩化金酸溶液とクエン酸溶液を調製した。次に、500mlの三口フラスコ内に、塩化金酸溶液6mlと超純水200mlとを投入して、30分間加熱還流させた。液温が安定した後、クエン酸溶液50mlを混合して、15分間加熱還流した。その後、加熱を停止して室温で放冷し、核コロイドを形成させた。尚、超純水の代わりにイオン交換水や蒸留水を使用することもできる。
上記方法によって形成した3.0×10−4mol/Lの核コロイド(平均粒径15.22nm)52mlを、500mlの三口フラスコに入れ、液温が30℃になるまで恒温層内で撹拌した。液温が安定したら、塩化金酸四水和物0.34g(8.2×10−4mol)を超純水50mlに溶解させ、そのうちの9.2mlを201mlまで希釈した塩化金酸溶液と、L−アスコルビン酸ナトリウム0.07g(3.5×10−4mol)を超純水204mlに溶解させたL−アスコルビン酸溶液204mlとを、2.0ml/minの速度で同時に滴下して、1時間撹拌しながら反応させて、成長段階を1回行った。得られた金コロイドの溶液は、ワインレッド色であった。尚、塩化金酸及びL−アスコルビン酸ナトリウムの添加量は、目標粒径を30nm、定数αを1.4、βは3.3として、式1より算出した。
Claims (7)
- 金コロイドの製造方法において、
第一の金塩の溶液に第一の還元剤を添加し、核コロイド粒子を形成させる核形成段階と、
前記核コロイド粒子の溶液に、第二の金塩及び第二の還元剤を添加して核コロイドを成長させる成長段階とを含み、
前記成長段階は少なくとも1回以上行うものであり、
第一の還元剤にはクエン酸塩、第二の還元剤にはアスコルビン酸塩を用い、且つ、前記成長段階におけるアスコルビン酸塩の添加を第二の金塩の添加と同時に行なうことを特徴とする金コロイドの製造方法。 - 1回の成長段階において、第二の金塩とアスコルビン酸塩とを、それぞれ次式で示される量添加する請求項1に記載の金コロイドの製造方法。
- 第一の金塩及び/又は第二の金塩を、塩化金酸とする請求項1又は請求項2に記載の金コロイドの製造方法。
- 成長段階を1回行い、コロイド粒子の平均粒子径を17nm以上55nm未満とする請求項1〜請求項3のいずれか1項に記載の金コロイドの製造方法。
- 成長段階を2回行い、コロイド粒子の平均粒子径を55nm以上110nm未満とする請求項1〜請求項3のいずれか1項に記載の金コロイドの製造方法。
- 成長段階を3回行い、コロイド粒子の平均粒子径を110nm以上220nm以下とする請求項1〜請求項3のいずれか1項に記載の金コロイドの製造方法。
- 請求項1〜請求項6のいずれか1項に記載の金コロイドの製造方法により得られた金コロイドであって、粒径の標準偏差が10%以内の金コロイド。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006156041A JP4970851B2 (ja) | 2006-06-05 | 2006-06-05 | 金コロイドの製造方法及び金コロイド |
US12/298,313 US8048193B2 (en) | 2006-06-05 | 2007-05-29 | Method for producing gold colloid and gold colloid |
PCT/JP2007/060919 WO2007142082A1 (ja) | 2006-06-05 | 2007-05-29 | 金コロイドの製造方法及び金コロイド |
EP07744338.0A EP2027956B1 (en) | 2006-06-05 | 2007-05-29 | Process for production of colloidal gold |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006156041A JP4970851B2 (ja) | 2006-06-05 | 2006-06-05 | 金コロイドの製造方法及び金コロイド |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007321232A JP2007321232A (ja) | 2007-12-13 |
JP4970851B2 true JP4970851B2 (ja) | 2012-07-11 |
Family
ID=38801339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006156041A Active JP4970851B2 (ja) | 2006-06-05 | 2006-06-05 | 金コロイドの製造方法及び金コロイド |
Country Status (4)
Country | Link |
---|---|
US (1) | US8048193B2 (ja) |
EP (1) | EP2027956B1 (ja) |
JP (1) | JP4970851B2 (ja) |
WO (1) | WO2007142082A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110189483A1 (en) * | 2007-04-20 | 2011-08-04 | Williams Marsh Rice University | Gram-Scale Synthesis of Well-Defined Gold Nanorods |
SE533902C2 (sv) | 2009-09-22 | 2011-02-22 | Small Particle Technology Gbg Ab | Nanopartiklar av silver |
US9925592B2 (en) * | 2010-09-24 | 2018-03-27 | Nanyang Technological University | Method for fabricating a gold nanoparticle |
JP5358648B2 (ja) * | 2010-11-05 | 2013-12-04 | 田中貴金属工業株式会社 | 免疫学的測定用青色金ナノ粒子、その製造方法およびそれを用いた測定方法 |
US9581590B2 (en) | 2011-11-09 | 2017-02-28 | Board Of Trustees Of Michigan State University | Metallic nanoparticle synthesis with carbohydrate capping agent |
CN102565409B (zh) * | 2011-12-31 | 2014-04-30 | 上海凯创生物技术有限公司 | 一种苯二氮卓类药物检测试剂盒及其制备 |
CN102539786B (zh) * | 2011-12-31 | 2014-06-04 | 上海凯创生物技术有限公司 | 微量尿白蛋白胶体金检测试剂盒及其制备工艺 |
CN102539773B (zh) * | 2011-12-31 | 2014-07-16 | 上海凯创生物技术有限公司 | 氯胺酮胶体金检测试剂盒及其制备方法 |
CN102590521B (zh) * | 2012-02-27 | 2014-07-30 | 上海凯创生物技术有限公司 | 快速检测咖啡因的胶体金检测试剂盒及其制备工艺 |
CN102590520B (zh) * | 2012-02-27 | 2014-04-09 | 上海凯创生物技术有限公司 | Eddp胶体金检测试剂盒及其制备方法 |
WO2016007942A1 (en) * | 2014-07-11 | 2016-01-14 | Northwestern University | Synthesis of uniform anisotropic nanoparticles |
CN105067807B (zh) * | 2015-04-30 | 2018-01-09 | 珠海丽珠试剂股份有限公司 | 一种免疫检测用纳米胶体金的制备方法 |
CN105436516B (zh) * | 2015-12-03 | 2018-06-08 | 南昌大学 | 可控粒径高吸光强度多枝状胶体金纳米粒子的制备方法 |
TWI648099B (zh) | 2017-06-19 | 2019-01-21 | 健鼎科技股份有限公司 | 金屬奈米粒子膠體溶液的製法 |
GB2563611B (en) * | 2017-06-20 | 2019-06-12 | Tripod Technology Corp | Method of making colloidal metal nanoparticles |
US10099191B1 (en) | 2017-06-22 | 2018-10-16 | Tripod Technology Corporation | Method of making colloidal metal nanoparticles |
CN113000852B (zh) * | 2021-02-09 | 2023-08-25 | 中国科学院合肥物质科学研究院 | 一种亚微米级或微米级单分散单晶导电金球及其制备方法 |
CN115575623B (zh) * | 2022-12-06 | 2023-03-28 | 深圳市卓润生物科技有限公司 | 胶体金及其制备方法和应用 |
US11897855B1 (en) | 2023-07-11 | 2024-02-13 | King Faisal University | Antioxidant vitamin C derivative |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63274706A (ja) | 1987-05-02 | 1988-11-11 | Nippon Chem Ind Co Ltd:The | 金属微粉末の製造法 |
JPS63307208A (ja) * | 1987-06-08 | 1988-12-14 | Chiyoda Chem Eng & Constr Co Ltd | 貴金属微粉末の製造方法 |
JPH0372683A (ja) * | 1989-08-11 | 1991-03-27 | Toshiba Corp | 反射型センサ |
JP3072683B2 (ja) * | 1992-10-26 | 2000-07-31 | 富士電機株式会社 | 電気接触子 |
JP2834400B2 (ja) | 1994-01-18 | 1998-12-09 | 鐘紡株式会社 | 金コロイド溶液 |
JP2902954B2 (ja) | 1994-09-20 | 1999-06-07 | 鐘紡株式会社 | 金コロイド溶液の製造方法および金コロイド溶液 |
JPH10317022A (ja) * | 1997-05-22 | 1998-12-02 | Daiken Kagaku Kogyo Kk | 金属微粒子粉末の製造方法 |
US6689190B2 (en) | 2001-12-20 | 2004-02-10 | Cima Nanotech, Inc. | Process for the manufacture of reacted nanoparticles |
WO2006099312A2 (en) * | 2005-03-10 | 2006-09-21 | Northwestern University | Method of producing triangular or spherical gold nanoprisms starting from seeds |
-
2006
- 2006-06-05 JP JP2006156041A patent/JP4970851B2/ja active Active
-
2007
- 2007-05-29 EP EP07744338.0A patent/EP2027956B1/en active Active
- 2007-05-29 WO PCT/JP2007/060919 patent/WO2007142082A1/ja active Application Filing
- 2007-05-29 US US12/298,313 patent/US8048193B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8048193B2 (en) | 2011-11-01 |
EP2027956A1 (en) | 2009-02-25 |
JP2007321232A (ja) | 2007-12-13 |
US20100159471A1 (en) | 2010-06-24 |
EP2027956A4 (en) | 2010-09-15 |
WO2007142082A1 (ja) | 2007-12-13 |
EP2027956B1 (en) | 2017-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4970851B2 (ja) | 金コロイドの製造方法及び金コロイド | |
Yang et al. | Anisotropic nanomaterials for shape-dependent physicochemical and biomedical applications | |
CN103038161B (zh) | 固有磁性的羟基磷灰石 | |
US20120046482A1 (en) | Method for synthesizing gold nanoparticles | |
C-W Wu et al. | Facile synthesis of hollow mesoporous hydroxyapatite nanoparticles for intracellular bio-imaging | |
EP2657223B1 (en) | Metal-salen complex compound and production method for same | |
KR100873176B1 (ko) | 할로겐 이온을 이용한 다양한 결정형의 금 나노입자의합성방법 | |
CN105209079A (zh) | 具有中心腔的基于金属氧化物纳米颗粒的磁共振成像造影剂 | |
CN107427586A (zh) | 具有过氧化氢酶样活性的edds螯合纳米铈氧化物 | |
US9631032B2 (en) | Method for manufacturing hydroxyethyl starch derivatives | |
CN103768620A (zh) | Fe/介孔氧化硅纳米复合材料及其制备方法和应用 | |
TW202120483A (zh) | 放射性金屬錯合體之製造方法 | |
JPWO2002079091A1 (ja) | 塩基性金属硝酸塩の製造法 | |
JP2015508796A (ja) | PEG置換α−ヒドロキシホスホネート外殻を有する超常磁性ナノ粒子 | |
Yamada et al. | Synthesis of luminescent Eu (III)-doped octacalcium phosphate particles hybridized with succinate ions and their reactive behavior in simulated body fluid | |
Yang et al. | Acid-Resistant Near-Infrared II Ag2Se Quantum Dots for Gastrointestinal Imaging | |
Kaasalainen et al. | Lithiated porous silicon nanowires stimulate periodontal regeneration | |
JP6200950B2 (ja) | 耐熱性ナノ粒子標品並びに関連方法 | |
WO2017054037A1 (en) | Controlled growth of three-dimensional heterogeneous nanocrystals | |
KR20140136638A (ko) | 치료와 진단이 동시에 가능한 나노 캡슐 구조의 유-무기 나노복합체 및 이의 제조방법 | |
JP2001097720A (ja) | 酸化ニッケル粉末の製造方法 | |
CN109365832B (zh) | 一种Fe3O4@Au复合材料的合成方法 | |
Wang et al. | Magnetocaloric‐Responsive Hydrogel Nanoarchitectonics for Pyroptosis‐Relay‐Immunotherapy to Suppress Post‐Operation Tumor Recurrence and Metastasis | |
JP5662036B2 (ja) | ヒ素を含有する溶液からの結晶性ヒ酸鉄の生成方法 | |
JP6449706B2 (ja) | スコロダイトの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081212 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20100318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120323 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120405 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4970851 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |